The high-sensitivity modified Glasgow prognostic score is superior to the modified Glasgow prognostic score as a prognostic predictor for head and neck cancer

Abstract

BackgroundThere is increasing evidence that the inflammatory indices of modified Glasgow prognostic score (mGPS) and high-sensitivity mGPS (HS-mGPS) play important roles in predicting the survival in many cancer; however, evidence supporting such an association in head and neck cancer (HNC) is scarce.Materials and MethodsWe evaluated the impact of the mGPS and HS-mGPS on the overall survival (OS) in 129 patients with HNC treated at Aichi Cancer Center Central Hospital from 2012-2013. The mGPS was calculated as follows: mGPS of 0, C-reactive protein (CRP) ≤1.0 mg/dl; 1, CRP >1.0 mg/dl; 2, CRP>1.0 mg/dl and albumin <3.5 mg/dl. Regarding the HS-mGPS, the CRP threshold level was set as 0.3 mg/dl. Hazard ratios (HRs) and 95% confidence intervals (95% CIs) were estimated by Cox proportional hazard models after adjusting for potential confounders.ResultsThe prognosis of HNC worsened significantly as both the mGPS and HS-mGPS increased in a univariate analysis. After adjusting for covariates, the HS-mGPS was significantly associated with the OS (adjusted HR for HS-mGPS of 2 compared to an HS-mGPS of 0 [HRscore2-0] 3.14 [95% CI: 1.23-8.07], Ptrend < 0.001), while the mGPS was suggested to be associated with the survival (HRscore2-0 2.37 [95% CI:0.89-6.33], Ptrend = 0.145). Even after stratification by clinical covariates, these associations persisted.ConclusionWe conclude that the HS-mGPS is useful as an independent prognostic factor in HNC.

Prognostic Value of High-Sensitivity Modified Glasgow Prognostic Score in Castration-Resistant Prostate Cancer Patients Who Received Docetaxel

“…Their results suggested a serum CRP level of 0.3 mg/dL is a potentially significant threshold and improves the prognostic importance of the mGPS. The prognostic superiority of the Hs-mGPS over mGPS has been demonstrated in many series of nonurological malignancies such as neck and esophageal cancer [ 24 , 25 ]. For example, in 2020, Tao Hou et al reported that the Hs-mGPS was significantly associated with overall survival and disease-free survival in patients with soft-tissue sarcoma who underwent radical surgery [ 26 ].…”

Impacts of Inflammation‐Based Prognostic Scores on Survival in Patients With Hypopharyngeal Squamous Cell Carcinoma

“…Hanai et al 25 reported that high-sensitivity mGPS (HS-mGPS) is effective in head and neck cancer areas. We plan to further investigate the prognostic factors of hypopharyngeal cancer by comparing mGPS with HS-mGPS in future studies.…”

Inflammatory biomarkers as independent prognosticators of 28-day mortality for COVID-19 patients admitted to general medicine or ICU wards: a retrospective cohort study

“…The mGPS is a composite of two common inflammatory biomarkers: CRP and albumin, both of which have individually been investigated in this analysis. The mGPS is validated for prognostication of relapse and increased mortality in different types of cancer [ 25 – 27 ], and can also predict clinical outcomes in patients with heart failure with preserved ejection fraction [ 28 ] While no studies to date have investigated its usefulness in COVID-19, we have demonstrated that mGPS is a potential tool for predicting risk of 28-day mortality. For a score of 2 vs. 1 or 0, we found an absolute increase of 26.3% (26.3% vs. 0.0%) mortality risk.…”